home.aspx
 
. https://pharmaceutical.report/Resources/Whitepapers/8b8056b4-f38a-44f4-9b82-6aa1968c12bc_OncoMabs.pdf
whitepaper
SHARESHARESHARE
PHARMA IS ATTRACTED TO ANTIBODY DEALS IN ONCOLOGY
Antibody therapeutics clearly offer clinical benefi ts over cheaper, older and mainly generic cytotoxic drugs. However, due to their high development and manufacturing costs and the cost to payers, they tend to get used as later-stage treatments only to extend life by a relatively limited amount. This sometimes makes the cost to payers hard to justify and increases the need for biomarkers to deliver personalised treatments where reimbursement will be limited to just those patients who will gain signifi cant benefi t. DOWNLOAD